Targets › ADRA1B
28 programs from 27 companies in 49 trials: 17 Phase 4, 12 Phase 2, 11 Phase 3, 9 Phase 1; Other, Cardiovascular, Neurology; next expected readout Dec 2026.
Alpha-1 adrenergic receptors are G protein-coupled receptors for catecholamines that signal through the G(q) family of G proteins, including G(q) and G(11). Upon activation, they stimulate the phosphatidylinositol-calcium second messenger pathway, leading to calcium release from intracellular stores and activation of protein kinase C (By similarity). (UniProt, P35368)
Open in Phaseline: the race on ADRA1B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Chicago | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Shock | Dec 2026 |
| Sohag University | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia | Mar 2027 |
| University of Alberta | Midodrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Vasoplegia | Mar 2027 |
| James J. Peters Veterans Affairs Medical Center | Midodrine Hydrochloride Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Hypotension | Jun 2027 |
| Seoul National University Hospital | Phenoxybenzamine Adrenergic receptor alpha antagonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 4 | Pheochromocytoma | Aug 2027 |
| University of Alberta | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Vasoconstriction | Dec 2027 |
| Dalian Municipal Central Hospital | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Hypotension Drug-Induced | – |
| Rawalpindi Medical College | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Phenylephrine | – |
| Hassan II University | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 4 | Cesarean Section Complications | – |
| VA Office of Research and Development | Prazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Posttraumatic Stress Disorder | Dec 2026 |
| Bir Hospital | Tamsulosin Hydrochloride Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Ureteral Stent-Related Symptom | Dec 2026 |
| Penang Hospital, Malaysia | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Stent Related Symptoms | May 2027 |
| CHU de Quebec-Universite Laval | Tamsulosin hydrochloride Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Urinary Retention | Jul 2027 |
| Opus Genetics | Phentolamine Ophthalmic Solution 0.75% Non-selective alpha-1 and alpha-2 adrenergic antagonist | ADRA1A, ADRA1B, ADRA1D, ADRA2A | Phase 3 | Vision Loss Night; Insulin Resistance | Aug 2027 |
| University College, London | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 3 | Parkinsons Disease (PD) | May 2031 |
| Cairo University | OraVerse (phentolamine mesylate) Alpha-adrenergic antagonist and vasodilator that reverses local anesthetic effects by bloc | ADRA1A, ADRA1B | Phase 3 | Soft Tissue Injuries | – |
| Santen SAS | Oxymetazoline (STN1013800) Adrenergic receptor alpha agonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 3 | Acquired Blepharophimosis; Sleep Apnea; Perioperative Respiratory Adverse Events; Nasal Obstruction | – |
| Brown University | Doxazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Alcohol Use Disorder (AUD) | Dec 2026 |
| University of Wisconsin, Madison | Prazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Magnetic Resonance Imaging | May 2027 |
| University of Aarhus | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Hypotension | Dec 2027 |
| Ottawa Heart Institute Research Corporation | Midodrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Heart Failure With Reduced Ejection Fraction | Jun 2028 |
| Cedars-Sinai Medical Center | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | REM Sleep Behavior Disorder; Symptomatic Parkinson Disease | – |
| Shaheed Mohtarma Benazir Bhutto Institue of Trauma | Xylometazoline nasal drops 0.1% Alpha-1 and alpha-2 adrenergic agonist for vasoconstriction | ADRA1A, ADRA1B, ADRA2A | Phase 2 | Nasal Bleeding | – |
| Kingston Health Sciences Centre | phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 2 | Shock | – |
| University of Manitoba | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Blood Loss, Surgical | Jun 2028 |
| Montefiore Medical Center | Phenylephrine Adrenergic receptor alpha-1 agonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Mitral Regurgitation | – |
| Berlin-Chemie AG Menarini Group | Tamsulosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Healthy Volunteers; Healthy Adult Males Volunteers; Healthy Volunteer Male Subjects; Nephrolithiasis … | – |
| University of Iowa | Terazosin Adrenergic receptor alpha-1 antagonist | ADRA1A, ADRA1D, ADRA1B | Phase 1 | Healthy | – |
Stent Related Symptoms (2) Urinary Retention (2) Hypotension (2) Phenylephrine (2) Magnetic Resonance Imaging (2) Shock (2) Parkinsons Disease (PD) (1) REM Sleep Behavior Disorder (1) Symptomatic Parkinson Disease (1) Pheochromocytoma (1) Ureteral Stent-Related Symptom (1) Vasoplegia (1)
small molecule (27)
University of Alberta (2) University College, London (1) Cedars-Sinai Medical Center (1) Seoul National University Hospital (1) Bir Hospital (1) Santen SAS (1) Berlin-Chemie AG Menarini Group (1) Brown University (1) James J. Peters Veterans Affairs Medical Center (1) Shaheed Mohtarma Benazir Bhutto Institue of Trauma (1) University of Iowa (1) Ottawa Heart Institute Research Corporation (1) Dalian Municipal Central Hospital (1) Sohag University (1) Rawalpindi Medical College (1) University of Aarhus (1) VA Office of Research and Development (1) University of Manitoba (1) University of Wisconsin, Madison (1) University of Chicago (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.